•  
  •  
 

Corresponding Author

Laklouk, Mahmoud

Document Type

Original Article

Abstract

Background: Recurrent miscarriages are common in around 1% of couples. Although the origin of antiphospholipid syndrome is unclear in the majority of instances, it is a preventable cause. Antiphospholipid antibody syndrome (APS) is a disorder marked by arterial and venous thrombosis, as well as gestation difficulties, when antiphospholipid (aPL) antibodies are present. Preeclampsia, placental inadequacy, and fetal development limitation are among the pregnancy difficulties in women with APS, as well as repeated miscarriages and fetal mortality. Aim of The Study: The purpose was to see how varied timings for starting low-molecular-weight heparin (LMWH) and aspirin therapy affected pregnancy end results in women with antiphospholipid syndrome and recurring abortion. Patients and Methods: randomized clinical trial study, the study was carried out on 100 participants was collected from outpatient clinic till fulfill sample size as they seek to be pregnant in next months, according to following criteria, the participants was collected from outpatient clinic of gynecological and obstetric department of Sayed Galal university hospitals. Results: Our findings demonstrated that giving LMWH to gestational women with obstetrical APS early in the pregnancy decreased fetal loss by a substantial amount, while increase live birth but this results was insignificant; it was found that the two groups showed insignificant difference regarding maternal complication, but the neonatal complication was significantly lower in early administration of LMWH. Conclusion: Early LMWH therapy for pregnant women with obstetrical APS lowers the risk of fetal loss and neonatal problems, but has little effect on the risk of late obstetrical difficulties.

Keywords

Low-molecular; weight heparin; Aspirin -Antiphospholipid syndrome; recurrent abortion

Download

Share

COinS